Combined with IFN-DC-based vaccination, the immunomodulatory drug, lenalidomide, which was approved for R/R FL patients [2] and active for untreated FL [174] and MCL patients [28,175], increased the frequency of IFN-γ production by NK cells in response to Karpas-422, a DLBCL cell line harboring t(14,18) translocation [176]. This evidence concerns the gene IFNA1 and mantle cell lymphoma.